PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
03-Aug-2022 U.S. Food and Drug Administration (FDA) Approves FYB201/CIMERLITM* (ranibizumab-eqrn), the First and Only Biosimilar Interchangeable with Lucentis®** B3C newswire
03-Aug-2022 Invitation: Straumann Group 2022 half-year financial results webcast Straumann Holding AG
03-Aug-2022 Becoming a cannabis ecosystem: SynBiotic SE management update SynBiotic SE
03-Aug-2022 U.S. Food and Drug Administration (FDA) approved FYB201/CIMERLITM1 (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®2 Formycon AG
03-Aug-2022 Antibiotic Research UK Announces New CEO Sciad Newswire
03-Aug-2022 Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2 Formycon AG
03-Aug-2022 Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil) Relief Therapeutics Holding SA
02-Aug-2022 iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference iTeos Therapeutics
02-Aug-2022 Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases Sosei Heptares
02-Aug-2022 BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal BioXcel Therapeutics
02-Aug-2022 atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update atai Life Sciences
02-Aug-2022 Defence Therapeutics Inc.: BREAKTHROUGH DISCOVERY: ACCUTOXTM EFFECTIVELY KILLS CANCER CELLS BY DIRECTLY ELICITING DNA DAMAGE Defence Therapeutics Inc.
01-Aug-2022 Medios AG: Contract of CEO Matthias Gaertner extended ahead of schedule Medios AG
01-Aug-2022 PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY PAION AG
01-Aug-2022 BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology B3C newswire
31-Jul-2022 Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022 (news with additional features) Vivoryon Therapeutics N.V.
31-Jul-2022 Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O (news with additional features) Vivoryon Therapeutics N.V.
30-Jul-2022 Dermapharm commits to acquire the French market leader for herbal medicinal products and food supplements Dermapharm Holding SE
30-Jul-2022 Dermapharm Holding SE: binding offer to acquire Arkopharma Group Dermapharm Holding SE
29-Jul-2022 Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include Monkeypox Bavarian Nordic